1. need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. 2. hemoglobin \<10 g/dl in men and \<9 g/dl in women. 3. platelet count \<100,000/ µl or received a platelet transfusion within 5 days prior to enrollment. 4. was on dialysis or has an estimated glomerular filtration rate \<30 ml/min/1.73 m\^2 5. aspartate aminotransferase (ast)/alanine aminotransferase (alt) \>3x upper limit normal (uln). 6. history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, were excluded. 7. history of kidney disease as evidenced by estimated creatinine clearance value \<30 ml/min. 8. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4\<200/mm\^3) and/or on treatment with nucleos(t)ide analogues. 9. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, (e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and convalescent plasma), or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. 10. receipt of a sars-cov-2 vaccination prior to study entry. 11. known allergy/sensitivity or any hypersensitivity to components of molnupiravir, or its formulation. 12. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 13. history of recent (within the past 3 months) hemorrhagic cerebrovascular accident) or major bleed. 14. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

1. need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. 2. hemoglobin \<10 g/dl in men and \<9 g/dl in women. 3. platelet count \<100,000/ µl or received a platelet transfusion within 5 days prior to enrollment. 4. was on dialysis or has an estimated glomerular filtration rate \<30 ml/min/1.73 m\^2 5. aspartate aminotransferase (ast)/alanine aminotransferase (alt) \>3x upper limit normal (uln). 6. history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, were excluded. 7. history of kidney disease as evidenced by estimated creatinine clearance value \<30 ml/min. 8. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4\<200/mm\^3) and/or on treatment with nucleos(t)ide analogues. 9. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, (e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and convalescent plasma), or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. 10. receipt of a sars-cov-2 vaccination prior to study entry. 11. known allergy/sensitivity or any hypersensitivity to components of molnupiravir, or its formulation. 12. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 13. history of recent (within the past 3 months) hemorrhagic cerebrovascular accident) or major bleed. 14. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. hemoglobin <10 g/dl in men and <9 g/dl in women. platelet count <100,000/ µl or received a platelet transfusion within 5 days prior to enrollment. was on dialysis or has an estimated glomerular filtration rate <30 ml/min/1.73 m^2 aspartate aminotransferase (ast)/alanine aminotransferase (alt) >3x upper limit normal (uln). history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, were excluded. history of kidney disease as evidenced by estimated creatinine clearance value <30 ml/min. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm^3) and/or on treatment with nucleos(t)ide analogues. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, (e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and convalescent plasma), or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. receipt of a sars-cov-2 vaccination prior to study entry. known allergy/sensitivity or any hypersensitivity to components of molnupiravir, or its formulation. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. history of recent (within the past 3 months) hemorrhagic cerebrovascular accident) or major bleed. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. hemoglobin <10 g/dl in men and <9 g/dl in women. platelet count <100,000/ µl or received a platelet transfusion within 5 days prior to enrollment. was on dialysis or has an estimated glomerular filtration rate <30 ml/min/1.73 m^2 aspartate aminotransferase (ast)/alanine aminotransferase (alt) >3x upper limit normal (uln). history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, were excluded. history of kidney disease as evidenced by estimated creatinine clearance value <30 ml/min. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm^3) and/or on treatment with nucleos(t)ide analogues. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, (e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and convalescent plasma), or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. receipt of a sars-cov-2 vaccination prior to study entry. known allergy/sensitivity or any hypersensitivity to components of molnupiravir, or its formulation. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. history of recent (within the past 3 months) hemorrhagic cerebrovascular accident) or major bleed. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. hemoglobin <10 g/dl in men and <9 g/dl in women. platelet count <125,000/l. estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 aspartate aminotransferase (ast)/alanine aminotransferase (alt) ≥3x upper limit normal (uln). history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, are excluded. history of significant kidney disease in the opinion of the site investigator. note: if the individual responds "yes" but can provide a creatinine clearance value ≥60 ml/min by cockcroft gault equation within 1 year prior to study entry, the individual may participate. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm3) and/or on treatment with nucleoside analogues. history of known blood dyscrasia use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. receipt of a sars-cov-2 vaccination prior to study entry. known allergy/sensitivity or any hypersensitivity to components of eidd-2801, or its formulation. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. history of recent hemorrhagic cerebrovascular accident (cva) or major bleed. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. hemoglobin <10 g/dl in men and <9 g/dl in women. platelet count <125,000/l. estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 aspartate aminotransferase (ast)/alanine aminotransferase (alt) ≥3x upper limit normal (uln). history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, are excluded. history of significant kidney disease in the opinion of the site investigator. note: if the individual responds "yes" but can provide a creatinine clearance value ≥60 ml/min by cockcroft gault equation within 1 year prior to study entry, the individual may participate. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm3) and/or on treatment with nucleoside analogues. history of known blood dyscrasia use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. receipt of a sars-cov-2 vaccination prior to study entry. known allergy/sensitivity or any hypersensitivity to components of eidd-2801, or its formulation. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. history of recent hemorrhagic cerebrovascular accident (cva) or major bleed. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

1. need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. 2. hemoglobin <10 g/dl in men and <9 g/dl in women. 3. platelet count <125,000/l. 4. estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 5. aspartate aminotransferase (ast)/alanine aminotransferase (alt) ≥3x upper limit normal (uln). 6. history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, are excluded. 7. history of significant kidney disease in the opinion of the site investigator. note: if the individual responds "yes" but can provide a creatinine clearance value ≥60 ml/min by cockcroft gault equation within 1 year prior to study entry, the individual may participate. 8. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm3) and/or on treatment with nucleoside analogues. 9. history of known blood dyscrasia 10. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. 11. receipt of a sars-cov-2 vaccination prior to study entry. 12. known allergy/sensitivity or any hypersensitivity to components of eidd-2801, or its formulation. 13. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 14. history of recent hemorrhagic cerebrovascular accident (cva) or major bleed. 15. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.

1. need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. 2. hemoglobin <10 g/dl in men and <9 g/dl in women. 3. platelet count <125,000/l. 4. estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 5. aspartate aminotransferase (ast)/alanine aminotransferase (alt) ≥3x upper limit normal (uln). 6. history of or current hospitalization for covid-19. note: individuals hospitalized and then discharged, even if only hospitalized for 1 day, are excluded. 7. history of significant kidney disease in the opinion of the site investigator. note: if the individual responds "yes" but can provide a creatinine clearance value ≥60 ml/min by cockcroft gault equation within 1 year prior to study entry, the individual may participate. 8. history of significant liver disease in the opinion of the site investigator or active hepatitis b or active hepatitis c. human immunodeficiency virus (hiv) that is advanced (cd4<200/mm3) and/or on treatment with nucleoside analogues. 9. history of known blood dyscrasia 10. use of therapeutic interventions with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. 11. receipt of a sars-cov-2 vaccination prior to study entry. 12. known allergy/sensitivity or any hypersensitivity to components of eidd-2801, or its formulation. 13. active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 14. history of recent hemorrhagic cerebrovascular accident (cva) or major bleed. 15. presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.